SPARC Surges 11% as US Court Clears Priority Review Voucher for Sezaby

Sun Pharma Advanced Research Company (SPARC) rallied nearly 11 percent today, extending its two-day winning streak, after a US court ruled in its favour regarding the Priority Review Voucher (PRV) linked to its drug Sezaby. The court stated that the FDA’s earlier refusal to grant the PRV was not justified, reinforcing SPARC’s claim that Sezaby qualifies for the voucher. Sezaby, an FDA-approved injectable phenobarbital formulation for neonatal seizures, had already given SPARC a strong regulatory breakthrough. With the PRV now cleared, SPARC gains access to a high-value asset that can either be used to fast-track a future drug application or be sold for significant monetisation. PRVs are rare, and their market value often runs into hundreds of crores. Why the stock is rising The PRV confirmation strengthens SPARC’s innovation profile and improves the commercial strategic value of Sezaby. The voucher gives SPARC optionality: accelerate its own pipeline or generate large non-operational income through a sale. The ruling brings regulatory clarity, reducing uncertainty around one of its key assets. What to watch next The FDA has a window to challenge the ruling; any update could impact short-term sentiment. How SPARC leverages the PRV — monetisation, partnerships, or pipeline acceleration — will determine long-term benefits. Execution on Sezaby’s commercial rollout and new R&D developments will remain critical drivers. If you found this post helpful, do follow me for more such insights!